2022-10-24-Capgemini-量子在生命科学中的未来-生命科学组织可以采取4项行动来实现可扩展的量子计算战略（英）_13页_486kb

The Future of Quantum in Life Sciences

Core Content

Quantum computing is emerging as a transformative technology with the potential to revolutionize the life sciences industry, particularly in drug discovery and development. The industry currently faces high costs and long timelines in bringing new drugs to market, with an average development timeline of 10 years and a cost exceeding $1 billion. Quantum computing offers a new paradigm that can enhance modeling, optimize processes, and simulate complex molecular interactions with unprecedented accuracy.

Main Opportunities for Quantum in Life Sciences

• Drug Discovery and Optimization: Quantum can simulate drug-target interactions and assist in identifying lead compounds through quantum machine learning.
• Molecular Design: Quantum optimization can help in selecting the best candidate molecules for synthesis and testing, reducing time and cost.
• In Silico Predictions: Quantum-native models can provide new, flexible approaches for predicting molecular properties and classifications.

Potential Quantum Timeline

Key Actions for Life Sciences Organizations

1. Calibrate the R&D Investment

   • Avoid over-investing in quantum at this stage.
   • Make strategic, modest investments to build capabilities.
   • Integrate quantum into long-term R&D planning.

2. Develop a Quantum Roadmap

   • Create a dedicated roadmap for quantum initiatives.
   • Plan proofs of concept and define expected outcomes.
   • Monitor progress and adapt as necessary to avoid overcommitment or premature termination.

3. Build Quantum Skills and Expertise

   • Focus on developing internal quantum capabilities.
   • Identify and retrain existing R&D staff with relevant skills (e.g., data science, AI).
   • Hire experts in quantum algorithms and applications.

4. Develop a Partner Ecosystem

   • Engage with quantum technology partners to stay informed and aligned with industry trends.
   • Build relationships within the quantum ecosystem to guide investments and manage change effectively.

Risks of Inaction

Delaying quantum investments may lead to missing out on competitive advantages. As the technology matures, the ability to simulate and optimize complex biological systems will become increasingly critical. Companies that wait for certainty may find themselves at a disadvantage in a rapidly evolving field.

Quantum Readiness with Capgemini

Capgemini is positioned to support life sciences organizations in their quantum journey through:

• A dedicated Quantum Lab
• Long-term IBM Quantum partnership
• A deep bench of quantum engineers
• Industry-specific knowledge in both pharma and medtech

These resources help organizations explore quantum's impact, build necessary skills, and develop scalable strategies for the future.

Conclusion

Quantum computing, while not yet mature enough for widespread commercial use, is on a rapid development path. Life sciences organizations should begin preparing now to capitalize on its potential when it becomes viable. The ability to simulate, optimize, and predict molecular behavior with quantum could lead to faster, more efficient, and more successful drug development processes.

Sources

1. Hingorani, A.D., Kuan, V., Finan, C. et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep 9, 18911 (2019). https://doi.org/10.1038/s41598-019-54849-w
2. https://phrma.org/policy-issues/Research-and-Development-Policy-Framework
3. Schlander, M., Hernandez-Villafuerte, K., Cheng, CY. et al. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics 39, 1243–1269 (2021). https://doi.org/10.1007/s40273-021-01065-y
4. Scannell, J., Blanckley, A., Boldon, H. et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11, 191-200 (2012). https://doi.org/10.1038/nrd3681

Contact

• Andrew Alderman
  Director Life Sciences & Healthcare, Hybrid Intelligence
  Capgemini Engineering
  andrew.alderman@capgemini.com

• Sam Genway
  Global Life Sciences Quantum Lead, Capgemini
  Sam.genway@capgemini.com